patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Free
Message: NASDAQ

I agree.  Not only nullifying the manipulation factor but also creating a lot more exposure for larger investors.

The downside is that PLRS has to have some substantial news in order to survive on the NASDAQ.  PLRS will drop fast without any substantial news.  The NASDAQ also has more exposure to "shorting".  Hopefully they've got something substantial to announce. 

 How do you know Frank Carlucci wanted this stock on the NAZ?  Is there something in writing that states this?

 Thanks for your help!

Share
New Message
Please login to post a reply